Overview

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Status:
Terminated
Trial end date:
2016-07-18
Target enrollment:
Participant gender:
Summary
Assess the body's reaction to dose-response relationship for the adalimumab/Methotrexate interaction in subjects with moderately to severely active ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Alimentiv Inc.
University of Western Ontario, Canada
Collaborator:
Abbott
Treatments:
Adalimumab
Methotrexate